Case Western Reserve University

Other

Mirx Pharmaceuticals, LLC

Invenio Therapeutics Inc.

David Wald

Mahesh Kumar Gundluru

Mukesh Agarwal

Goutam Karan

Zhiqing Xia

Zhiqiang Xia

The present disclosure relates to methods for expanding and increasing the cytotoxic activity of natural killer cells comprising co-culturing, as feeder cells, a population of myeloid leukemia cells engineered to express one or more of membrane-bound IL-21 (mb IL-21) or membrane-bound IL-15 (mbIL-15) in the presence of cytokine support. The present disclosure also relates to a population of acute myeloid leukemia cells engineered to express one or more of membrane-bound IL-21 (mbIL-21) or membrane-bound IL-15 (mbIL-15). The present disclosure also relates to methods of treating cancer employing the step of expanding natural killer cells using feeder cells engineered to express one or more of membrane-bound IL-21 (mbIL-21) or membrane-bound IL-15 (mbIL-15).

Compositions for expanding natural killer cells

The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders

Myeloid differentiating agents can be used in the treatment of myeloid proliferative disorders.

Myeloid differentiation inducing agents

The present invention provides for novel acridine-like class of compounds that have demonstrated efficiency in treating cancer. The compounds of the present invention have demonstrated efficacy in binding to and antagonizing the activity of the p53 repressor, HDMX. Once administered to a cell, the compounds of the present invention bind HDMX, thereby allowing p53 to induce apoptosis of the cancerous cell. A combination of this class of compounds along with Nutlin3 provides a novel approach to treat cancers.

HDMX inhibitors and their use for cancer treatment

The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.

Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase

The present application relates to securinine or norsecurinine analogs that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases. The agents may also be used as a myeloablative agent in conjunction with a bone marrow transplant or stem cell therapy.

The present invention relates to novel securinine and norsecurine analogs and their applicapility in treating cellular proliferative disorders.

Small molecule securinine and norsecurinine analogs and their use in cancers, inflammatory diseases and infections

Myeloid differentiating agents can be used in the treatment of myeloid disorders.

Growing community of inventors

Shaker Heights, OH, United States of America

David Wald